Status:
UNKNOWN
Intravenous Magnesium Sulphate in Acute Ischemic Stroke
Lead Sponsor:
Dow University of Health Sciences
Conditions:
Stroke
Ischemic Stroke
Eligibility:
All Genders
45-95 years
Phase:
EARLY_PHASE1
Brief Summary
Magnesium has a neuroprotective role so the investigators aim to evaluate the role of intravenous magnesium sulphate in improving the clinical outcomes as assessed by the NIH Stroke Scale (NIHSS) in p...
Eligibility Criteria
Inclusion
- Adults with a confirmed diagnosis of ischemic stroke on neurological examination and CT scan findings aged between 45 -95 years of age of either gender.
- Adults presenting within a stroke onset of 24 hours.
Exclusion
- Patients with confirmed diagnosis other than ischemic stroke (evidence of Intracranial bleed or space occupying lesion)
- Subjects with systolic blood pressure less than 90mmHg
- Presence of Bundle Branch block or atrioventricular block.
- Serum Creatinine \> 3mg/dl
- Respiratory failure (O2 saturation \<90% or Respiratory Rate \>24 or \<12)
- Pregnancy.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04412850
Start Date
December 1 2020
End Date
August 1 2021
Last Update
June 2 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.